ustransplant Home | Contact us | Site Map
About the SRTRExpand About the SRTR
|
National Transplant StatisticsExpand National Transplant Statistics
|
Program and OPO DataExpand Program and OPO Data
|
Research ResourcesExpand Research Resources
Publication Details

CITATION:
Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 2009; 50(20): 400-406

Click for the article in PubMed Go to PubMed links
ABSTRACT:
Disease-specific analysis of liver transplant survival benefit, which encompasses both pre- and posttransplant events, has not been reported. Therefore, we evaluated the effect of alcoholic liver disease (ALD) and hepatitis C virus (HCV) infection on waiting list mortality, posttransplant mortality, and the survival benefit of deceased donor liver transplantation using United States data from the Scientific Registry of Transplant Recipients on 38,899 adults placed on the transplant waiting list between September 2001 and December 2006. Subjects were classified according to the presence/absence of HCV and ALD. Cox regression was used to estimate waiting list mortality and posttransplant mortality separately. Survival benefit was assessed using sequential stratification. Overall, the presence of HCV significantly increased waiting list mortality, with a covariate-adjusted hazard ratio (HR) for HCV-positive (HCV+) compared with HCV-negative (HCV-) HR = 1.19 (P = 0.0001). The impact of HCV+ was significantly more pronounced (P = 0.001) among ALD-positive (ALD+) patients (HR = 1.36; P < 0.0001), but was still significant among ALD-negative (ALD-) patients (HR = 1.11; P = 0.02). The contrast between ALD+ and ALD- waiting list mortality was significant only among HCV+ patients (HR = 1.14; P = 0.006). Posttransplant mortality was significantly increased among HCV+ (versus HCV-) patients (HR = 1.26; P = 0.0009), but not among ALD+ (versus ALD-) patients. Survival benefit of transplantation was significantly decreased among HCV+ compared with HCV- recipients with model for end-stage liver disease (MELD) scores 9-29, but was significantly increased at MELD >or=30. ALD did not influence the survival benefit of transplantation at any MELD score. CONCLUSION: Except in patients with very low or very high MELD scores, HCV status has a significant negative impact on the survival benefit of liver transplantation. In contrast, the presence of ALD does not influence liver transplant survival benefit.

Information for Patients and Families Information for Transplant Community and Policy Makers Information for Researchers
Spacer Choose an audience
Transplant Program and OPO Specific Data
Fast Facts give an overview of recent waiting list and transplant activity


Contact the SRTR

315 W. Huron St.
Suite 360
Ann Arbor, MI 48103 USA
Tel: +1 (800) 830-9664
Fax: +1 (734) 665-2103
Email Us

The SRTR is administered by the Arbor Research Collaborative for Health with the University of Michigan,
with oversight and funding from the Health Resources and Services Administration.

About the SRTR | National Transplant Statistics | Program and OPO Data | Research Resources | Privacy Statement 		Spacer
Spacer